Article information
Resumen
Los pacientes con psoriasis presentan un riesgo incrementado de accidentes cardiovasculares, y existe una correlación entre los fenómenos inmunológicos que ocurren en la psoriasis y otros procesos inflamatorios crónicos, como la ateromatosis. La aparición de eventos adversos cardiovasculares mayores en pacientes con psoriasis en placas en tratamiento con ustekinumab ha producido alarma en algunos autores; sin embargo, un análisis detallado de los estudios realizados confirma la seguridad cardiovascular de ustekinumab.
Palabras clave:
Ustekinumab
MACES
Psoriasis
Seguridad cardiovascular
Abstract
Patients with psoriasis have an increased risk of cardiovascular events, and there is evidence of a correlation between the immune processes that occur in psoriasis and those seen in other chronic inflammatory disorders such as atheromatous disease. The occurrence of major cardiovascular events in patients with plaque psoriasis being treated with ustekinumab caused alarm among some researchers, but a thorough analysis of the findings to date has confirmed the cardiovascular safety of this agent.
Keywords:
Ustekinumab
Major cardiovascular events
Psoriasis
Cardiovascular safety
Full text is only aviable in PDF
References
[1.]
C.E. Griffiths, J.N. Barker.
Pathogenesis and clinical features of psoriasis.
Lancet, 370 (2007), pp. 263-271
[2.]
J. Koo.
Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.
Dermatol Clin, 14 (1996), pp. 485-496
[3.]
National Psoriasis Foundation. Psoriasis Statistics. Disponible en: http://www.psoriasis.org/about/stats.
[4.]
S.C. Weiss, A.B. Kimball, D.J. Liewehr, A. Blauvelt, M.L. Turner, E.J. Emanuel.
Quantifying the harmful effect of psoriasis on health-related quality of life.
J Am Acad Dermatol, 47 (2002), pp. 512-518
[5.]
J. Hong, B. Koo, J. Koo.
The psychosocial and occupational impact of chronic skin disease.
Dermatol Ther, 21 (2008), pp. 54-59
[6.]
A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, A.B. Troxel, J.M. Gelfand, et al.
Prevalence of cardiovascular risk factors in patients with psoriasis.
J Am Acad Dermatol, 55 (2006), pp. 829-835
[7.]
A.B. Kimball, Y. Wu.
Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis.
Int J Dermatol, 48 (2009), pp. 1147-1156
[8.]
C.J. McDonald, P. Calabresi.
Psoriasis occlusive vascular disease.
Br J Dermatol, 99 (1978), pp. 469-475
[9.]
G. Krueger, C.N. Ellis.
Psoriasis-recent advances in understanding its pathogenesis and treatment.
J Am Acad Dermatol, 53 (2005), pp. S94-S100
[10.]
F. Späh.
Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach.
Br J Dermatol, 159 (2008), pp. 10-17
[11.]
J.B. Meigs, P.W. Wilson, C.S. Fox, R.S. Vasan, D.M. Nathan, L.M. Sullivan, et al.
Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease.
J Clin Endocrinol Metab, 91 (2006), pp. 2906-2912
[12.]
G. Assmann, H. Schulte, U. Seedorf.
Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study.
Int J Obes (Lond), 32 (2008), pp. S11-S16
[13.]
R.H. Eckel, S.M. Grundy, P.Z. Zimmet.
The metabolic syndrome.
Lancet, 365 (2005), pp. 1415-1428
[14.]
J.M. Calbo Mayo, I. Terrancle de Juan, P. Fernádez Jiménez, M.J. Rodríguez Martín, V. Martínez Díaz, I. Santisteban López, et al.
Grupo de Estudio Síndrome Metabólico de Albacete Prevalence of metabolic syndrome in the province of Albacete (Spain).
Rev Clin Esp, 207 (2007), pp. 64-68
[15.]
P. Gisondi, G. Tessari, A. Conti, S. Piaserico, S. Schianchi, A. Peserico, et al.
Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study.
Br J Dermatol, 157 (2007), pp. 68-73
[16.]
D.M. Sommer, S. Jenisch, M. Suchan, E. Christophers, M. Weichenthal.
Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis.
Arch Dermatol Res, 298 (2006), pp. 321-328
[17.]
J.C. Ruiz-Carrascosa, S. Arias-Santiago.
Psoriasis y síndrome metabólico.
Piel, 25 (2010), pp. 133-145
[18.]
K. Poikolainen, J. Karvonen, E. Pukkala.
Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis.
Arch Dermatol, 135 (1999), pp. 1490-1493
[19.]
U. Mrowietz, J.T. Elder, J. Barker.
The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients.
Arch Dermatol Res, 298 (2006), pp. 309-319
[20.]
S. Jankovic, M. Raznatovic, J. Marinkovic, J. Jankovic, N. Maksimovic.
Risk factors for psoriasis: a case-control study.
J Dermatol, 36 (2009), pp. 328-334
[21.]
M.H. Criqui.
The roles of alcohol in the epidemiology of cardiovascular diseases.
Acta Med Scand Suppl, 717 (1987), pp. 73-85
[22.]
A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, A.B. Troxel, J.M. Gelfand.
Prevalence of cardiovascular risk factors in patients with psoriasis.
J Am Acad Dermatol., 55 (2006), pp. 829-835
[23.]
F. Sampogna, S. Tabolli, D. Abeni, IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Investigators.
The impact of changes in clinical severity on psychiatric morbidity in patients with psoriasis: a follow-up study..
Br J Dermatol, 157 (2007), pp. 508-513
[24.]
M. Sopori.
Effects of cigarette smoke on the immune system.
Nat Rev Immunol, 2 (2002), pp. 372-377
[25.]
A. Aicher, C. Heeschen, M. Mohaupt, J.P. Cooke, A.M. Zeiher, S. Dimmeler.
Nicotine strongly activates dendritic cell-mediated adaptive immunity: potential role for progression of atherosclerotic lesions.
Circulation, 107 (2003), pp. 604-611
[26.]
S.A. Grando, R.M. Horton, T.M. Mauro, D.A. Kist, T.X. Lee, M.V. Dahl.
Activation of keratinocyte nicotinic cholinergic receptors stimulates calcium influx and enhances cell differentiation.
J Invest Dermatol, 107 (1996), pp. 412-418
[27.]
M.D. Winniford, D.E. Jansen, G.A. Reynolds, P. Apprill, W.H. Black, L.D. Hillis.
Cigarette smoking-induced coronary vasoconstriction in atherosclerotic coronary artery disease and prevention by calcium antagonists and nitroglycerin.
Am J Cardiol, 59 (1987), pp. 203-207
[28.]
I.M. Graham, L.E. Daly, H.M. Refsum, K. Robinson, L.E. Brattström, P.M. Ueland.
Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project.
JAMA, 277 (1997), pp. 1775-1781
[29.]
M. Malerba, P. Gisondi, A. Radaeli, R. Sala, P.G. Calzavara Pinton, G. Girolomoni.
Plasma homocysteine and folate levels in patients with chronic plaque psoriasis.
Br J Dermatol, 155 (2006), pp. 1165-1169
[30.]
L. Fry, A. Macdonald, J. Almeyda, C.J. Griffin, A.V. Hoffbrand.
The mechanism of folate deficiency in psoriasis.
Br J Dermatol, 84 (1971), pp. 539-544
[31.]
R. Scarpa, F. Manguso, A. D’Arienzo, F.P. D’Armiento, C. Astarita, G. Mazzacca, et al.
Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms.
J Rheumatol, 27 (2000), pp. 1241-1246
[32.]
J.C. Peterson, J.D. Spence.
Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia.
Lancet, 351 (1998), pp. 263
[33.]
A. Salim, E. Tan, A. Ilchyshyn, J. Berth-Jones.
Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial.
Br J Dermatol, 154 (2006), pp. 1169-1174
[34.]
B. Vanizor Kural, A. Orem, G. Cimşit, Y.E. Yandi, M. Calapoglu.
Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis.
Clin Chim Acta, 328 (2003), pp. 71-82
[35.]
S. Boehncke, D. Thaci, H. Beschmann, R.J. Ludwig, H. Ackermann, K. Badenhoop, et al.
Psoriasis patients show signs of insulin resistance.
Br J Dermatol, 157 (2007), pp. 1249-1251
[36.]
I.N. Bruce, C.T. Schentag, D.D. Gladman.
Hyperuricemia in psoriatic arthritis: prevalence and associated features.
J Clin Rheumatol, 6 (2000), pp. 6-9
[37.]
A.L. Gaffo, N.L. Edwards, K.G. Saag.
Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?.
Arthritis Res Ther, 11 (2009), pp. 240
[38.]
J. Gajardo.
Clinical experience with etretinate (Tigason) in 26 patients with psoriasis.
Rev Med Chil, 117 (1989), pp. 516-522
[39.]
A.B. Gottlieb, F. Chamian, S. Masud, I. Cardinale, M.V. Abello, M.A. Lowes, et al.
TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques.
J Immunol, 175 (2005), pp. 2721-2729
[40.]
S. Prodanovich, F. Ma, J.R. Taylor, C. Pezon, T. Fasihi, R.S. Kirsner.
Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.
J Am Acad Dermatol, 52 (2005), pp. 262-267
[41.]
K. Gong, Z. Zhang, X. Sun, X. Zhang, A. Li, J. Yan, et al.
The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure..
Am Heart J, 151 (2006), pp. 62-68
[42.]
W.G. Dixon, K.D. Watson, M. Lunt, K.L. Hyrich, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ Symmons DP; British Society for Rheumatology Biologics Register.
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
Arthritis Rheum, 56 (2007), pp. 2905-2912
[43.]
P. Gisondi, C. Cotena, G. Tessari, G. Girolomoni.
Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
J Eur Acad Dermatol Venereol, 22 (2008), pp. 341-344
[44.]
B. Yazdani-Biuki, T. Mueller, H.P. Brezinschek, J. Hermann, W. Graninger, T.C. Wascher.
Relapse of diabetes after interruption of chronic administration of anti-tumor necrosis factor-alpha antibody infliximab: a case observation.
Diabetes Care, 29 (2006), pp. 1712-1713
[45.]
J.J. Wu, T.F. Tsai.
Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis.
Arch Dermatol, 144 (2008), pp. 1403-1404
[46.]
D. Hürlimann, A. Forster, G. Noll, F. Enseleit, R. Chenevard, O. Distler, et al.
Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis.
Circulation, 106 (2002), pp. 2184-2187
[47.]
L.T. Jacobsson, C. Turesson, A. Gülfe, M.C. Kapetanovic, I.F. Petersson, T. Saxne, et al.
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.
J Rheumatol, 32 (2005), pp. 1213-1218
[48.]
K. Uyemura, L.L. Demer, S.C. Castle, D. Jullien, J.A. Berliner, M.K. Gately, et al.
Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis.
J Clin Invest, 97 (1996), pp. 2130-2138
[49.]
P. Davenport, P.G. Tipping.
The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice.
Am J Pathol, 163 (2003), pp. 1117-1125
[50.]
T.S. Lee, H.C. Yen, C.C. Pan, L.Y. Chau.
The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice.
Arterioscler Thromb Vasc Biol, 19 (1999), pp. 734-742
[51.]
A.D. Hauer, C. Uyttenhove, P. De Vos, V. Stroobant, J.C. Renauld, T.J. Van Berkel, et al.
Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis.
Circulation, 112 (2005), pp. 1054-1062
[52.]
G.G. Krueger, R.G. Langley, C. Leonardi, N. Yeilding, C. Guzzo, Y. Wang, CNTO 1275 Psoriasis Study Group, et al.
A human interleukin-12/13 monoclonal antibody for the treatment of psoriasis.
N Engl J Med, 356 (2007), pp. 580-592
[53.]
C.L. Leonardi, A.B. Kimball, K.A. Papp, N. Yeilding, C. Guzzo, Y. Wang, PHOENIX 1 study investigators, et al.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results form a randomized, double-blind, placebo-controlled trial (PHOENIX 1).
Lancet, 371 (2008), pp. 1665-1674
[54.]
K.A. Papp, R.G. Langley, M. Lebwohl, G.G. Krueger, P. Szapary, N. Yeilding, PHOENIX 2 study investigators, et al.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results form a randomized, double-blind, placebo-controlled trial (PHOENIX 2).
Lancet, 371 (2008), pp. 1675-1684
[55.]
C. Griffits, A. Menter, B. Strober, R. Fidelus-Gort.
A phase III, multicenter, randomized study comparing ustekinumab and etanercept for the treatment of moderate to severe plaque psoriasis.
Abstract. J Am Acad Dermatol., 60 (2009), pp. AB166
[56.]
Gordon K, Leonardi C, Lebwohl M. The ustekinumab safety experience in patients with moderate-to-severe psoriasis: Results from pooled analyses on phase 2 and phase 3 clinical trial data. 18th Congress of the European Academy of Dermatology. Berlin, 7–11 Oct 2009.
[57.]
K. Reich, R.G. Langley, M. Lebwohl, P. Szapary, C. Guzzo, N. Yeilding, et al.
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.
Br J Dermatol, 164 (2011), pp. 862-872
[58.]
D. Lloyd-Jones, R.J. Adams, T.M. Brown, M. Carnethon, S. Dai, G. De Simone, et al.
American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics-2010 update: a report from the American Heart Associations.
Circulation, 121 (2010), pp. e46-e215
[59.]
Framingham SNP. Health Association Resource.;1; Study Accession: phs000007.v11.p5. (Última consulta 15/02/2011). Disponible en: http://www.ncbi.nlm.nih.gov/projects/gap/cgibin/study.cgi?study_id=phs000007.v11.p5.
[60.]
C. Ryan, C.L. Leonardi, J.G. Kueger, A.B. Kimball, B.E. Strober, K.B. Gordon, et al.
Association between biologic therapies for chronic plaque psoriasis cardiovascular events: a meta-analysis of randomized controlled trials.
JAMA, 306 (2011), pp. 864-871
[61.]
D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, PRISMA Group.
Preferred reporting items for systematic reviews metaanalyses: PRISMA. statement.
BMJ, 339 (2009), pp. b2535
[62.]
M. Wakkee, H.B. Thio, E.P. Prens, E.J. Sijbrands, H.A. Neumann.
Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients.
Atherosclerosis, 190 (2007), pp. 1-9
[63.]
G.K. Hansson.
Inflammation atherosclerosis, and coronary artery disease.
N Engl J Med, 352 (2005), pp. 1685-1695
[64.]
A. Tedgui, Z. Mallat.
Cytokines in atherosclerosis: pathogenic and regulatory pathways.
Physiol Rev, 86 (2006), pp. 515-581
[65.]
M. Mangino, P. Braund, R. Singh, R Steeds, S. Stevens, K S Channer, et al.
Association analysis of IL-12B and IL-23R polymorphisms in myocardial infarction..
J Mol Med (Berl), 86 (2008), pp. 99-103
[66.]
J.M. Gelfand, A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, A.B. Troxel.
Risk of myocardial infarction in patients with psoriasis.
JAMA, 296 (2006), pp. 1735-1741
[67.]
J.M. Gelfand, E.D. Dommasch, D.B. Shin, R.S. Azfar, S.K. Kurd, X. Wang, et al.
The risk of stroke in patients with psoriasis.
J Invest Dermatol, 129 (2009), pp. 2411-2418
[68.]
N.N. Mehta, R.S. Azfar, D.B. Shin, A.L. Neimann, A.B. Troxel, J.M. Gelfand.
Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database.
Eur Heart J, 31 (2010), pp. 1000-1006
Copyright © 2012. Academia Española de Dermatología y Venereología
